Heartflow, Inc.
HTFLNasdaq
$24.88
↓ -4.2%Jul 17 close · end-of-day
Price
1Y↓ -13.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.1B
Enterprise Value
$2.0B
P/E
14.1
P/S
11.1
P/B
7.5
EV/EBITDA
—
PEG
—
FCF Yield
-3.6%
Dividend Yield
—
Revenue (TTM)
$191.4M
Net Income (TTM)
-$111.8M
Free Cash Flow (TTM)
-$76.8M
Gross Margin
78.1%
Operating Margin
-39.7%
Net Margin
-58.4%
ROE
-39.1%
ROIC
-47.2%
Debt / Equity
—
Net Cash
$158.3M
Return 1Y
—
Company profile
We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. Our principal executive offices are located in Mountain View, California.
- CEO
- John C.M. Farquhar
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 699
- Headquarters
- California
- Website
- www.heartflow.com/
Management & directors
- Rogers CampbellChief Medical Officer
- Farquhar John C.M.Chief Executive Officer
- Jones Marie L.Chief Accounting Officer, VP
- Verghese VikramChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
HTFL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$52.6M↑ +41.3%
Diluted EPS-$0.32↓ -93.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $87.2M | $125.8M | $176.0M |
| Gross profit | $58.1M | $94.4M | $135.2M |
| Operating income | -$72.9M | -$61.2M | -$64.1M |
| Net income | -$95.7M | -$96.4M | -$116.8M |
| Diluted EPS | -$25.32 | -$17.98 | -$3.17 |
| Operating cash flow | -$76.4M | -$69.0M | -$54.0M |
| Free cash flow | -$82.5M | -$73.4M | -$59.0M |
| Gross margin | 66.6% | 75.1% | 76.8% |
| Operating margin | -83.6% | -48.7% | -36.4% |
| Net margin | -109.7% | -76.6% | -66.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.1M | $32.9M | — | $37.2M | $43.4M | $46.3M | $49.1M | $52.6M |
| Gross profit | $23.8M | $24.9M | — | $27.9M | $32.8M | $35.4M | $39.1M | $42.2M |
| Operating income | -$14.2M | -$14.9M | — | -$17.5M | -$13.7M | -$15.1M | -$17.8M | -$29.5M |
| Net income | -$23.4M | -$19.1M | -$33.0M | -$32.3M | -$9.2M | -$50.9M | -$24.4M | -$27.4M |
| Diluted EPS | -$4.66 | -$3.43 | — | -$5.25 | -$1.46 | -$1.04 | $4.58 | -$0.32 |
| Operating cash flow | — | -$10.3M | — | -$13.2M | -$27.3M | -$3.0M | -$10.6M | -$30.1M |
| Free cash flow | — | -$11.3M | — | -$14.3M | -$28.1M | -$4.2M | -$12.5M | -$32.0M |
| Gross margin | 76.8% | 75.7% | — | 75.1% | 75.5% | 76.5% | 79.5% | 80.2% |
| Operating margin | -45.7% | -45.3% | — | -47.0% | -31.6% | -32.6% | -36.1% | -56.1% |
| Net margin | -75.3% | -58.1% | — | -86.9% | -21.2% | -109.9% | -49.7% | -52.1% |
Company news
Jul 15, 2026
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Rogers Campbell· Chief Medical Officer | Sale | 9,219 | $25.72 | $237,112.68 | filing |
| 2026-07-15 | Rogers Campbell· Chief Medical Officer | Option exercise | 9,219 | $19.00 | $175,161.00 | filing |
| 2026-07-10 | Farquhar John C.M.· Chief Executive Officer | Sale | 22,562 | $27.75 | $626,095.50 | filing |
| 2026-07-08 | WELDON WILLIAM C | Option exercise | 17,123 | $8.33 | $142,634.59 | filing |
| 2026-07-08 | WELDON WILLIAM C | Option exercise | 17,123 | $8.33 | $142,634.59 | filing |
| 2026-07-08 | WELDON WILLIAM C | Option exercise | 17,123 | $8.33 | $142,634.59 | filing |
| 2026-06-24 | Farquhar John C.M.· Chief Executive Officer | Sale | 38,900 | $35.00 | $1.4M | filing |
| 2026-06-15 | Rogers Campbell· Chief Medical Officer | Option exercise | 10,000 | $2.22 | $22,200.00 | filing |
| 2026-06-10 | Farquhar John C.M.· Chief Executive Officer | Sale | 22,562 | $28.50 | $643,017.00 | filing |
| 2026-05-18 | Rogers Campbell· Chief Medical Officer | Sale | 9,219 | $28.34 | $261,266.46 | filing |
| 2026-05-18 | Rogers Campbell· Chief Medical Officer | Option exercise | 9,219 | $19.00 | $175,161.00 | filing |
| 2026-05-11 | Farquhar John C.M.· Chief Executive Officer | Sale | 22,562 | $29.12 | $657,005.44 | filing |
| 2026-05-07 | Farquhar John C.M.· Chief Executive Officer | Tax withholding | 1,904 | $29.98 | $57,081.92 | filing |
| 2026-05-07 | Rogers Campbell· Chief Medical Officer | Tax withholding | 637 | $29.98 | $19,097.26 | filing |
| 2026-05-07 | Verghese Vikram· Chief Financial Officer | Tax withholding | 473 | $29.98 | $14,180.54 | filing |
| 2026-05-07 | Jones Marie L.· Chief Accounting Officer | Tax withholding | 82 | $29.98 | $2,458.36 | filing |
| 2026-05-06 | Farquhar John C.M.· Chief Executive Officer | Tax withholding | 5,300 | $30.29 | $160,537.00 | filing |
| 2026-05-06 | Rogers Campbell· Chief Medical Officer | Tax withholding | 1,634 | $30.29 | $49,493.86 | filing |
| 2026-05-06 | Verghese Vikram· Chief Financial Officer | Tax withholding | 1,536 | $30.29 | $46,525.44 | filing |
| 2026-05-06 | Jones Marie L.· Chief Accounting Officer | Tax withholding | 485 | $30.29 | $14,690.65 | filing |
| 2026-04-30 | Bain Capital Life Sciences Investors, LLC | Sale | 892,533 | $29.18 | $26.0M | filing |
| 2026-04-30 | Bain Capital Life Sciences Investors, LLC | Sale | 56,224 | $30.05 | $1.7M | filing |
| 2026-04-29 | Bain Capital Life Sciences Investors, LLC | Sale | 797,133 | $29.37 | $23.4M | filing |
| 2026-04-28 | Bain Capital Life Sciences Investors, LLC | Sale | 254,110 | $30.51 | $7.8M | filing |
| 2026-04-10 | Farquhar John C.M.· Chief Executive Officer | Sale | 22,562 | $26.72 | $602,856.64 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.